RA0533

antibody from Oursmab

Targeting: NT5E CALJA, CD73, eN, eNT, NT5

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0533

Provider

Oursmab

Product name

Dresbuxelimab (Biosimilar Reference Antibody) (NT5E)

Antibody type

Monoclonal

Description

Dresbuxelimab (formerly AK119) is a humanized monoclonal antibody developed by Akeso Biopharma that targets CD73 (ecto-5'-nucleotidase). It is being investigated as an immunotherapy for cancer, aiming to inhibit the adenosine-mediated immunosuppressive pathway within the tumor microenvironment. By blocking CD73, dresbuxelimab seeks to enhance anti-tumor immune responses and is evaluated in clinical trials, often in combination with other immunotherapies such as PD-1/PD-L1 inhibitors, for the treatment of advanced solid tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Dresbuxelimab (Biosimilar Reference Antibody) (NT5E)-RA0533-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.